National Online Survey of Seniors Regarding the Medicare Part D Prescription Drug Benefit

There is no excerpt because this is a protected post.

Keep Reading

Response to XIL Consulting’s “Payers and PBMs Profit from Obscure Pharmacy Fees, While Seniors See No Relief in Prescription Costs”

A recent blog (“Payers and PBMs Profit from Obscure Pharmacy Fees, While Seniors See No Relief in Prescription Costs”) suggests performance-based price concessions are retained by PBMs, restrict the growth of independent pharmacies, and inflate Medicare Part D enrollee’s out-of-pocket costs—unfounded suggestions that evidence does not support.[1] Performance-based Pharmacy Reimbursement Saves Taxpayer Dollars and Helps Lower...

Keep Reading

Pharmacy Services Administrative Organizations (PSAOs) and their Little-Known Connections to Independent Pharmacies

Keep Reading

Podcast: The Impact of COVID-19 on the Pharmaceutical Market

JC Scott speaks with Doug Long, Vice President of Industry Relations at IQVIA, about the impact of COVID-19 on the pharmaceutical market. IQVIA is a world leader in using data, technology, advanced analytics and expertise to help customers drive healthcare – and human health – forward. JC Scott: Welcome to The Pharmacy Benefit, a podcast...

Keep Reading

Key Findings from Survey of Benefit Managers

Our national survey of benefit managers and human resources directors, conducted online June 4-9, 2020, consists of 250 respondents drawn from a list of benefit managers and human resources directors provided by Dynata. All respondents work for a company with 1,000 or more employees, have at least 1,000 individuals under coverage, and have an annual...

Keep Reading

Just the Facts: Pharmacy Direct and Indirect Remuneration Increases Value and Improves Quality

During the Energy and Commerce Health Subcommittee hearing on “The Fiscal Year 2021 HHS Budget and Oversight of the Coronavirus Outbreak” several inaccurate remarks were made on pharmacy direct and indirect remuneration (DIR). What is Pharmacy DIR? Pharmacy benefit managers (PBMs) and Part D plan sponsors use pharmacy DIR to create high-quality, value-based pharmacy networks,...

Keep Reading

High drug prices likely to continue in 2017, VCs say

Venrock partners Bob Kocher and Bryan Roberts predict that drug prices will continue to rise as copayment coupons desensitize patients to high prices; more drugstores will close as online shopping grows; and insurance premiums will rise, driven by regulatory uncertainty, high drug prices and hospital market power.

Keep Reading

Physicians support outcomes-based biopharmaceuticals pricing

Physicians voiced their support of outcomes-based pricing for experimental and expensive biopharmaceutical drugs in an Ideas and Opinions article published online in the Annals of Internal Medicine. The authors, led by Dr. Daniel Blumenthal of Massachusetts General Hospital, note that outcomes-based pricing could increase access to treatments while keeping costs down and “would compel manufacturers...

Keep Reading

PCMA-Connect

Keep Reading

The Medicare Prescription Drug Rebate Rule

Keep Reading